International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 42

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMENDÉES (DCI Rec): Liste 42

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 42

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

abaperidonum

abaperidone — 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3-(hydroxymethyl)-4*H*-1-benzopyran-4-one

abapéridone — 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)pipéridin-1-yl]propoxy]-3-(hydroxyméthyl)-4*H*-chromén-4-one

abaperidona — 7-[3-[4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino]propoxi]-3-(hidroximetil)-4*H*-1-benzopiran-4-ona

$C_{25}H_{25}FN_2O_5$



alitretinoinum

alitretinoin — (2*E*,4*E*,6*Z*,8*E*)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

alitrétinoïne — acide (2*E*,4*E*,6*Z*,8*E*)-3,7-diméthyl-9-(2,6,6-triméthylcyclohex-1-ényl)nona-2,4,6,8-tétraénoïque

alitretinoína — ácido (2*E*,4*E*,6*Z*,8*E*)-3,7-dimetil-9-(2,6,6-trimetil-1-ciclohexen-1-il)-2,4,6,8-nonatetraenoico

$C_{20}H_{28}O_2$



anecortavum

anecortave — 17,21-dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate

anécortave — 21-acétate de 17-hydroxy-3,20-dioxoprégna-4,9(11)-dién-21-yle

anecortava — 21-acetato de 17-hidroxi-3,20-dioxopregna-4,9(11)-dien-21-ilo

$C_{23}H_{30}O_5$



artemotilum

artemotil — (3*R*,5a*S*,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-10-ethoxydecahydro-3,6,9-trimethyl-3,12-epoxy-12*H*-pyrano[4,3-*j*]-1,2-benzodioxepin

artémotil — (3*R*,5a*S*,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-10-éthoxy-3,6,9-triméthyldécahydro-3,12-époxypyrano[4,3-*j*]-1,2-benzodioxépine

artemotilo — (3*R*,5a*S*,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-10-etoxidecahidro-3,6,9-trimetil-3,12-epoxi-12*H*-pirano[4,3-*j*]-1,2-benzodioxepina

$C_{17}H_{28}O_5$



arzoxifenum

arzoxifene — 2-(*p*-methoxyphenyl)-3-[*p*-(2-piperidinoethoxy)phenoxy]benzo[*b*]thiophene-6-ol

arzoxifène — 2-(4-méthoxyphényl)-3-[4-[2-(pipéridin-1-yl)éthoxy]phénoxy]benzo=[*b*]thiophén-6-ol

arzoxifeno — 2-(*p*-metoxifenil)-3-[*p*-(2-piperidinoetoxi)fenoxi]benzo[*b*]tiofeno-6-ol

$C_{28}H_{29}NO_4S$



atorolimumabum

atorolimumab — immunoglobulin G3, anti-(human Rh(D) antigen) (human monoclonal clone P3x22914G4 γ3-chain), disulfide with human monoclonal P3x22914G4 κ-chain, dimer

atorolimumab — immunoglobuline G3, anti-(antigène Rh(D) humain) (chaîne γ3 de l'anticorps monoclonal humain P3x22914G4), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain P3x22914G4

atorolimumab — inmunoglobulina G3, anti-(antígeno Rh(D) humano) (cadena γ3 del clon monoclonal humano P3x22914G4), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano P3x22914G4

avasimibum

avasimibe — 2,6-diisopropylphenyl[(2,4,6-triisopropylphenyl)acetyl]sulfamate

avasimibe — [[2,4,6-tris(1-méthyléthyl)phényl]acétyl]sulfamate de 2,6-bis-(1-méthyléthyl)phényle

avasimiba — [(2,4,6-triisopropilfenil)acetil]sulfamato de 2,6-diisopropilfenilo

$C_{29}H_{43}NO_4S$



bexarotenum

bexarotene — *p*-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid

bexarotène — acide 4-[1-(3,5,5,8,8-pentaméthyl-5,6,7,8-tétrahydronaphtalén-2-yl)éthényl]= benzoïque

bexaroteno — ácido *p*-[1-(5,6,7,8-tetrahidro-3,5,5,8,8-pentametil-2-naftil)vinil]benzoico

$C_{24}H_{28}O_2$



carabersatum

carabersat — *N*-[(3*R*,4*S*)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-*p*-fluorobenzamide

carabersate — *N*-[(3*R*,4*S*)-6-acétyl-3-hydroxy-2,2-diméthyl-3,4-dihydro-2*H*-chromén-4-yl]-4-fluorobenzamide

carabersato — *N*-[(3*R*,4*S*)-6-acetil-3-hidróxi-2,2-dimetil-4-cromanil]-*p*-fluorobenzamida

$C_{20}H_{20}FNO_4$



caspofunginum

caspofungin — (4*R*,5*S*)-5-[(2-aminoethyl)amino]-*N*^{2}-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(*S*)-4-hydroxy-4-(*p*-hydroxyphenyl)-L-threonyl-*threo*-3-hydroxy-L-ornithyl-*trans*-3-hydroxy-L-proline cyclic (6→1)-peptide

caspofungine — *N*-[(2*R*,6*S*,9*S*,11*R*,12*S*,14a*S*,15*S*,20*S*,23*S*,25a*S*)-12-[(2-aminoéthyl)amino]-20-[(1*R*)-3-amino-1-hydroxypropyl]-23-[(1*S*,2*S*)-1,2-dihydroxy-2-(4-hydroxyphényl)éthyl]-2,11,15-trihydroxy-6-[(1*R*)-1-hydroxyéthyl]-5,8,14,19,22,25-hexaoxotétracosahydro-1*H*-dipyrrolo[2,1-*c*:2',1'-*l*]=[1,4,7,10,13,16]hexaazacyclohénicosén-9-yl]-10,12-diméthyltétradécamide

caspofungina — (4*R*,5*S*)-5-[(2-aminoetil)amino]-*N*^{2}-(10,12-dimetiltetradecanoil)-4-hidroxi-L-ornitil-L-treonil-*trans*-4-hydroxy-L-prolil-(*S*)-4-hidroxi-4-(*p*-hidroxifenil)-L-treonil-*treo*-3-hidroxi-L-ornitil-*trans*-3-hidroxi-L-prolina, péptido cíclico (6→1)

$C_{52}H_{88}N_{10}O_{15}$



celecoxibum

celecoxib — *p*-[5-*p*-tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide

célécoxib — 4-[5-(4-méthylphényl)-3-(trifluorométhyl)-1*H*-pyrazol-1-yl]benzènesulfonamide

celecoxib — *p*-[5-*p*-tolil-3-(trifluorometil)pirazol-1-il]bencenosulfonamida

$C_{17}H_{14}F_3N_3O_2S$



corifollitropinum alfa

corifollitropin alfa — follicle-stimulating hormone (human α-subunit reduced), complex with follicle-stimulating hormone (human β-subunit reduced) fusion protein with 118-145-chorionic gonadotropin (human β-subunit)

corifollitropine alfa — hormone folliculostimulante modifiée formée de deux sous-unités α et β sous-unité α: gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine) sous-unité β: hormone folliculostimulante (partie protéique réduite de la sous-unité β humaine)-112-139-gonadotropine chorionique (partie protéique réduite de la sous-unité β humaine)

corifolitropina alfa — Hormona estimulante del folículo modificada, formada por dos subunidades α y β: Subunidad α: gonadotropina coriónica (fracción proteica reducida de la subunidad α humana) Subunidad β: hormona estimulante del folículo (fracción proteica reducida de la subunidad β humana)-112-139-gonadotropina coriónica (fracción proteica reducida de la subunidad β humana)

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP
LRSKKTMLVQ K*NVTSESTCC VAKSYNRVTV MGGFKVE*NHT
ACHCSTCYYH K*S

NSCELT*NITI AIEKEECRFC ISI*NTTWCAG YCYTRDLVYK
DPARPKIQKT CTFKELVYET VRVPGCAHHA DSLYTYPVAT
QCHCGKCDSD STDCTVRGLG PSYCSFGEMK ESSS*SKAPPP
*SLPSP*SRLPG P*SDTPILPQ*

* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

darbufelonum

darbufelone — 5-[(*Z*)-3,5-di-*tert*-butyl-4-hydroxybenzylidene]-2-imino-4-thiazolidinone

darbufélone — (*Z*)-5-[3,5-bis(1,1-diméthyéthyl)-4-hydroxybenzylidène]-2-iminothiazolidin-4-one

darbufelona — 5-[(*Z*)-3,5-di-*terc*-butil-4-hidroxibencilideno]-2-imino-4-tiazolidinona

$C_{18}H_{24}N_2O_2S$



depreotidum

depreotide — cyclo(L-homocysteinyl-*N*-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl), (1→1')-sulfide with 3-(2-mercaptoacetamido)-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamide

dépréotide — (1→1')-sulfure de cyclo[L-homocystéinyl-(*N*-méthyl-L-phénylalanyl)-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl] et de [3-[(sulfanylacétyl)amino]-L-alanyl]-L-lysyl-L-cystéinyl-L-lysinamide

depreotida — (1→1')-sulfuro de ciclo[L-homocisteinil-(*N*-metil-L-fenilalanil)-L-tirosil-D-triptofil-L-lisil-L-valilo] y 3-(2-mercaptoacetamido)-L-alanil-L-lisil-L-cisteinil-L-lisinamida

$C_{65}H_{96}N_{16}O_{12}S_2$



deracoxibum

deracoxib — *p*-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide

déracoxib — 4-[3-(difluorométhyl)-5-(3-fluoro-4-méthoxyphényl)-1*H*-pyrazol-1-yl]benzènesulfonamide

deracoxib — *p*-[3-(difluorometil)-5-(3-fluoro-4-metoxifenil)pirazol-1-il]bencenosulfonamida

$C_{17}H_{14}F_3N_3O_3S$



desloratadinum

desloratadine — 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5*H*-benzo[5,6]cyclohepta-[1,2-*b*]pyridine

desloratadine — 8-chloro-11-(pipéridin-4-ylidène)-6,11-dihydro-5*H*-benzo[5,6]cyclohepta-[1,2-*b*]pyridine

desloratadina — 8-cloro-6,11-dihidro-11-(4-piperidilideno)-5*H*-benzo[5,6]ciclohepta-[1,2-*b*]piridina

$C_{19}H_{19}ClN_2$



desmoteplasum

desmoteplase — plasminogen activator (*Desmodus rotundus,* isoform α1 protein moiety reduced)

desmotéplase — activateur du plasminogène (*Desmodus rotondus*, isoforme α1, partie protéique réduite)

desmoteplasa — activador del plasminógeno (isoforma α1, fracción proteica reducida de *Desmodus rotundus*)

dexbudesonidum

dexbudesonide — (*R*)-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,17-acetal with butyraldehyde

dexbudésonide — 16α,17-[(1*R*)-butylidènebis(oxy)]-11β,21dihydroxyprégna-1,4-diène-3,20-dione

dexbudesonida — 16,17-acetal butiraldehídico de (*R*)-11β,16α,17,21-tetrahidroxipregna-1,4-dieno-3,20-diona

$C_{25}H_{34}O_6$



ecopipamum

ecopipam (-)-(6a*S*,13b*R*)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5*H*-benzo[*d*]naphth[2,1-*b*]azepin-12-ol

écopipam (-)-(6a*S*,13b*R*)-11-chloro-7-méthyl-6,6a,7,8,9,13b-hexahydro-5*H*-benzo[*d*]naphto[2,1-*b*]azépin-12-ol

ecopipam (-)-(6a*S*,13b*R*)-11-cloro-6,6a,7,8,9,13b-hexahidro-7-metil-5*H*-benzo[d]naft=[2,1-*b*]azepin-12-ol

$C_{19}H_{20}ClNO$



emtricitabinum

emtricitabine 5-fluoro-1-[(2*R*,5*S*)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

emtricitabine 4-amino-5-fluoro-1-[(2*R*,5*S*)-2-(hydroxyméthyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1*H*)-one

emtricitabina 5-fluoro-1-[(2*R*,5*S*)-2-(hidroximetil)-1,3-oxatiolan-5-il]citosina

$C_8H_{10}FN_3O_3S$



enrasentanum

enrasentan — (1*S*,2*R*,3*S*)-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-1-[3,4-(methylenedioxy)phenyl]-5-propoxy-2-indancarboxylic acid

enrasentan — acide (1*S*,2*R*,3*S*)-1-(1,3-benzodioxol-5-yl)-3-[2-(2-hydroxyéthoxy)-4-méthoxyphényl]-5-propoxy-2,3-dihydro-1*H*-indène-2-carboxylique

enrasentano — ácido (1*S*,2*R*,3*S*)-3-[2-(2-hidroxietoxi)-4-metoxifenil]-1-[3,4-(metilenodioxi)fenil]-5-propoxi-2-indanocarboxílico

$C_{29}H_{30}O_8$



eplivanserinum

eplivanserin — (*E*)-2'-fluoro-4-hydroxychalcone (*Z*)-*O*-[2-(dimethylamino)ethyl]oxime

éplivansérine — (*E*)-1-(2-fluorophényl)-3-(4-hydroxyphényl)prop-2-énone (*Z*)-*O*-[2-(diméthylamino)éthyl]oxime

eplivanserina — (*Z*)-*O*-[2-(dimetilamino)etil]oxima de la (*E*)-2'-fluoro-4-hidroxicalcona

$C_{19}H_{21}FN_2O_2$



ethylcellulosum

ethylcellulose — cellulose ethyl ether

éthylcellulose — éther éthylique de cellulose

etilcelulosa — éter etílico de celulosa

etilevodopum

etilevodopa — (-)-3,4-dihydroxy-L-phenylalanine, ethyl ester

étilévodopa — (-)-(2*S*)-2-amino-3-(3,4-dihydroxyphényl)propanoate d'éthyle

etilevodopa — éster etílico de (-)-3,4-dihidroxi-L-fenilalanina

$C_{11}H_{15}NO_4$



exisulindum

exisulind — 5-fluoro-2-methyl-1-[(*Z*)-*p*-(methylsulfonyl)benzylidene]indene-3-acetic acid

exisulind — acide 2-[5-fluoro-2-méthyl-1-[(*Z*)-4-(méthylsulfonyl)benzylidène]-1*H*-indén-3-yl]acétique

exisulind — ácido 5-fluoro-2-metil-1-[(*Z*)-*p*-(metilsulfonil)bencilideno]indeno-3-acético

$C_{20}H_{17}FO_4S$



fanapanelum

fanapanel — [[3,4-dihydro-7-morpholino-2,3-dioxo-6-(trifluoromethyl)-1(2*H*)-quinoxalinyl]methyl]phosphonic acid

fanapanel — acide [[7-(morpholin-4-yl)-2,3-dioxo-6-(trifluorométhyl)-3,4-dihydroquinoxalin-1(2*H*)-yl]méthyl]phosphonique

fanapanel — ácido [[3,4-dihidro-7-morfolino-2,3-dioxo-6-(trifluorometil)-1(2*H*)-quinoxalinil]metil]fosfónico

$C_{14}H_{15}F_3N_3O_6P$



galarubicinum

galarubicin

(8*S*,10*S*)-10-[(2,6-dideoxy-2-fluoro-α-L-talopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 8^2-ester with β-alanine

galarubicine

3-aminopropanoate de 2-[(2*S*,4*S*)-4-[(2-fluoro-2,6-didésoxy-α-L-talopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotétracén-2-yl]-2-oxoéthyle

galarubicina

8*S*,10*S*)-8-(3-aminopropanoiloxiacetil)-10-[(2,6-didesoxi-2-fluoro-α-L-talopiranosil)=oxi]-7,8,9,10-tetrahidro-6,8,11-trihidroxi-1-metoxi-5,12-naftacenodiona

$C_{30}H_{32}FNO_{13}$



gantofibanum

gantofiban

4-[[(5*R*)-3-[*p*-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1-piperazineacetic acid, 1-ethyl methyl ester

gantofiban

2-[4-[[(5*R*)-3-[4-[(méthoxycarbonyl)carbamimidoyl]phényl]-2-oxooxazolidin-5-yl]méthyl]pipérazin-1-yl]acétate d'éthyle

gantofibán

4-[(5*R*)-3-[(4-metoxicarbonilaminoiminometil)fenil]-2-oxo-5-oxazolidinilmetil]-1-piperazinilacetato de etilo

$C_{21}H_{29}N_5O_6$



gimeracilum

gimeracil

5-chloro-2,4-pyridinediol

giméracil

5-chloropyridine-2,4-diol

gimeracilo

5-cloro-2,4-piridinadiol

$C_5H_4ClNO_2$



hemoglobinum glutamerum

hemoglobin glutamer	hemoglobin glutamer; the species specifity should be indicated in brackets behind the name, "(bovine)"; the average mass of the polymer is given as e.g., hemoglobin glutamer-250 for 250kD
hémoglobine glutamère	produit de la réaction du pentanedial avec l'hémoglobine; l'origine de l'hémoglobine doit être indiquée, "(bovine)"; la masse moléculaire moyenne doit être donnée, par exemple: hémoglobine glutamère-250 pour 250 kD
hemoglobina glutámero	hemoglobina polimerizada con glutaraldehído; debe indicarse entre paréntesis el origen del material, "(bovino)"; la masa del polímero medio se da como, por ej., hemoglobina glutámero-250 para 250kD

hyetellosum

hyetellose	cellulose 2-hydroxyethyl ether
hyétellose	éther 2-hydroxyéthylique de cellulose
hietelosa	éter 2-hidroxietílico de celulosa

hymetellosum

hymetellose	cellulose 2-hydroxyethyl methyl ether
hymétellose	éther 2-hydroxyéthylique et méthylique de cellulose
himetelosa	éter 2-hidroxílico metílico de celulosa

hyprolosum

hyprolose	cellulose 2-hydroxypropyl ether
hyprolose	éther 2-hydroxypropylique de cellulose
hiprolosa	éter 2-hidroxipropílico de celulosa

insulinum detemirum

insulin detemir	29^{B}-(N^{6}-myristoyl-L-lysine)-30^{B}-de-L-threonineinsulin (human)
insuline détémir	29^{B}-(N^{6}-tétradécanoyl-L-lysine)-30^{B}-dès-L-thréonineinsuline humaine
insulina detemir	29^{B}-(N^{6}-miristoil-L-lisina)-30^{B}-des-L-treoninainsulina (humana)

$C_{267}H_{402}N_{64}O_{76}S_6$



leridistimum

leridistim — 14-L-alanine-50-L-aspartic acid-14-125-interleukin 3 (human reduced) fusion protein with peptide (synthetic) linked with 17-L-serinegranulocyte colony-stimulating factor (human reduced)

léridistim — protéine de fusion entre la [14-L-alanine-50-acide L-aspartique]-14-125-interleukine 3 (humaine, réduite) et le [17-L-sérine]facteur de stimulation des colonies de granulocytes (humain, réduit)

leridistim — proteína de fusión de la [14-L-alanina-50-ácido L-aspártico]-14-125-interleucina-3 (humana reducida) con el [17-L-serina]factor de estimulación de las colonias de granulocitos (humano reducido)

$C_{1550}H_{2463}N_{425}O_{462}S_{12}$

ANCSNMIDEI ITHLKQPPLP LLDFNNLNGE DQDILMDNNL
RRPNLEAFNR AVKSLQNASA IESILKNLLP CLPLATAAPT
RHPIHIKDGD WNEFRRKLTF YLKTLENAQA QQYVEGGGGS
PGEPSGPIST INPSPPSKES HKSPNMATPL GPASSLPQSF
LLKSLEQVRK IQGDGAALQE KLCATYKLCH PEELVLLGHS
LGIPWAPLSS CPSQALQLAG CLSQLHSGLF LYQGLLQALE
GISPELGPTL DTLQLDVADF ATTIWQQMEE LGMAPALQPT
QGAMPAFASA FQRRAGGVLV ASHLQSFLEV SYRVLRHLAQ
P

leteprinimum

leteprinim — *p*-[3-(1,6-dihydro-6-oxo-9*H*-purin-9-yl)propionamido]benzoic acid

létéprinim — acide 4-[[3-(6-oxo-1,6-dihydro-9*H*-purin-9-yl)propanoyl]amino]benzoïque

leteprinim — ácido *p*-[3-(1,6-dihidro-6-oxo-9*H*-purin-9-il)propionamido]benzoico

$C_{15}H_{13}N_5O_4$



Iopinavirum

Iopinavir (αS)-tetrahydro-*N*-[(αS)-α-[(2*S*,3*S*)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)=acetamido]butyl]phenethyl]-α-isopropyl-2-oxo-1(2*H*)-pyrimidineacetamide

Iopinavir (2*S*)-*N*-[(1*S*,3*S*,4*S*)-1-benzyl-4-[[(2,6-diméthylphénoxy)acétyl]amino]-3-hydroxy-5-phénylpentyl]-3-méthyl-2-(2-oxotétrahydropyrimidin-1(2*H*)-yl)butanamide

Iopinavir (αS)-tetrahidro-*N*-[(αS)-α-[(2*S*,3*S*)-2-hidroxi-4-fenil-3-[2-(2,6-xililoxi)=acetamido]butil]fenetil]-α-isopropil-2-oxo-1(2*H*)-pirimidinacetamida

$C_{37}H_{48}N_4O_5$



Iusupultidum

Iusupultide glycyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-valyl-L-histidyl-L-leucyl-L-lysyl-L-arginyl-L-leucyl-L-leucyl-L-isoleucyl-L-valyl-L-valyl-L-valyl-L-valyl-L-valyl-L-valyl-L-leucyl-L-isoleucyl-L-valyl-L-valyl-L-valyl-L-isoleucyl-L-valylglycyl-L-alanyl-L-leucyl-L-leucyl-L-isoleucylglycyl-L-leucine

Iusupultide glycyl-L-isoleucyl-L-prolyl-L-phénylalanyl-L-phénylalanyl-L-prolyl-L-valyl-L-histidyl-L-leucyl-L-lysyl-L-arginyl-L-leucyl-L-leucyl-L-isoleucyl-L-valyl-L-valyl-L-valyl-L-valyl-L-valyl-L-valyl-L-leucyl-L-isoleucyl-L-valyl-L-valyl-L-valyl-L-isoleucyl-L-valyl-glycyl-L-alanyl-L-leucyl-L-leucyl-L-isoleucyl-glycyl-L-leucine

Iusupultida glycil-L-isoleucil-L-prolil-L-fenilalanil-L-fenilalanil-L-prolil-L-valil-L-histidil-L-leucil-L-lisil-L-arginil-L-leucil-L-leucil-L-isoleucil-L-valil-L-valil-L-valil-L-valil-L-valil-L-valil-L-valil-L-leucil-L-isoleucil-L-valil-L-valil-L-valil-L-isoleucil-L-valilglicil-L-alanil-L-leucil-L-leucil-L-isoleucilglicil-L-leucina

$C_{182}H_{310}N_{40}O_{35}$

Gly—Ile—Pro—Phe—Phe—Pro—Val—His—Leu—Lys—
10
Arg—Leu—Leu—Ile—Val—Val—Val—Val—Val—Val—
20
Leu—Ile—Val—Val—Val—Ile—Val—Gly—Ala—Leu—
30
Leu—Ile—Gly—Leu

maribavirum

maribavir — 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosylbenzimidazole

maribavir — 5,6-dichloro-*N*-(1-méthyléthyl)-1-(β-L-ribofuranosyl)-1*H*-benzimidazol-2-amine

maribavir — 5,6-dicloro-2-(isopropilamino)-1-β-L-ribofuranosilbenzimidazol
antiviral

$C_{15}H_{19}Cl_2N_3O_4$



minopafantum

minopafant — (+)-1-ethyl-2-[[*N*-[[(2*R*)-2-methoxy-3-[[[4-octadecylcarbamoyl)oxy]piperidino]=carbonyl]oxy]propoxy]carbonyl]-*o*-anisamido]methyl]pyridinium chloride

minopafant — (+)-chlorure de 1-éthyl-2-[[(2-méthoxybenzoyl)[[(2*R*)-2-méthoxy-3-[[[4-[(octadécylcarbamoyl)oxy]pipéridin-1-yl]carbonyl]oxy]propoxy]=carbonyl]amino]méthyl]pyridinium

minopafant — (+)-1-etil-2-[[*N*-[[(2*R*)-2-metoxi-3-[[[4-[(octadecilcarbamoil)oxi]piperidino]=carbonil]oxi]propoxi]carbonil]-*o*-anisamido]metil]piridinio

$C_{46}H_{73}ClN_4O_9$



minretumomabum

minretumomab — immunoglobulin G1 anti-(human tumor-associated glycoprotein 72) (mouse monoclonal Mab CC-49 γ1-chain), disulfide with mouse monoclonal Mab CC-49-chain, dimer

minrétumomab — immunoglobuline G1 anti-(glycoprotéine 72 humaine associée aux tumeurs) (chaîne γ1 de l'anticorps monoclonal de souris Mab CC-49), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris Mab CC-49

minretumomab — Inmunoglobulina G1 anti-(glicoproteína 72 humana asociada a los tumores) (cadena γ1 del anticuerpo monoclonal de ratón Mab CC-49), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón Mab CC-49

mivotilatum

mivotilate — isopropyl *N*-(4-methyl-2-thiazolyl)-1,3-dithietane-$\Delta^{2,\alpha}$-malonamate

mivotilate — 2-(1,3-dithiétan-2-ylidène)-3-[(4-méthylthiazol-2-yl)amino]-3-oxopropanoate de 1-méthyléthyle

mivotilato — *N*-(4-metil-2-tiazolil)-1,3-ditietano-$\Delta^{2,\alpha}$-malonamato de isopropilo

$C_{12}H_{14}N_2O_3S_3$



nelarabinum

nelarabine — 2-amino-β-D-arabinofuranosyl-6-methoxy-9*H*-purine

nélarabine — 9-(β-D-arabinofuranosyl)-6-méthoxy-9*H*-purin-2-amine

nelarabina — 2-amino-β-D-arabinofuranosil-6-metoxi-9*H*-purina

$C_{11}H_{15}N_5O_5$



nesiritidum

nesiritide

L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-L-histidine cyclic (10→26)-disulfide

nésiritide

1,32-facteur natriurétique (cerveau humain, clone λhBNP57)

nesiritida

(10→26)-disulfuro cílico de L-seril-L-prolil-L-lisil-L-metionil-L-valil-L-glutaminilglicil-L-serilglicil-L-cisteinil-L-fenilalanilglicil-L-arginil-L-lisil-L-metionil-L-aspartil-L-arginil-L-isoleucil-L-seril-L-seril-L-seril-L-serilglicil-L-leucilglicl-L-cisteinil-L-lisil-L-valil-L-leucil-L-arginil-L-arginil-L-histidina

$C_{143}H_{244}N_{50}O_{42}S_4$



olmesartanum

olmesartan

2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate

olmésartan

4-(1-hydroxy-1-méthyléthyl)-2-propyl-1-[4-[2-(1*H*-tétrazol-5-yl)phényl]benzyl]-1*H*-imidazole-5-carboxylate de (5-méthyl-2-oxo-1,3-dioxol-4-yl)méthyle

olmesartán

4-(1-hidroxi-1-metiletil)-2-propil-1-{[2'-(1*H*-tetrazol-5-il)-1,1'-bifenil-4-il]metil}-1*H*-imidazol-5-carboxilato de 5(metil-2-oxo-1,3-dioxolen-4-il)metilo

$C_{29}H_{30}N_6O_6$



oseltamivirum

oseltamivir

ethyl (3*R*,4*R*,5*S*)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate

oséltamivir

(3*R*,4*R*,5*S*)-4-(acétylamino)-5-amino-3-(1-éthylpropoxy)cyclohex-1-ène-1-carboxylate d'éthyle

oseltamivir

(3*R*,4*R*,5*S*)-4-acetamido-5-amino-3-(1-etilpropoxi)-1-ciclohexeno-1-carboxilato de etilo

$C_{16}H_{28}N_2O_4$



oteracilum

oteracil	1,4,5,6-tetrahydro-4,6-dioxo-*s*-triazine-2-carboxylic acid
otéracil	acide 4,6-dioxo-1,4,5,6-tétrahydro-1,3,5-triazine-2-carboxylique
oteracilo	ácido 1,4,5,6-tetrahidro-4,6-dioxo-*s*-triazina-2-carboxílico

$C_4H_3N_3O_4$



parecoxibum

parecoxib	*N*-[[*p*-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propionamide
parécoxib	*N*-[[4-(5-méthyl-3-phénylisoxazol-4-yl)phényl]sulfonyl]propanamide
parecoxib	*N*-[[*p*-(5-metil-3-fenil-4-isoxazolil)fenil]sulfonil]propionamida

$C_{19}H_{18}N_2O_4S$



pegacaristimum

pegacaristim	*N*-(3-hydroxypropyl)-1-163-megakaryocyte growth and development factor (human), monoether with polyethylene glycol monomethyl ether
pégacaristim	*N*-[3-[[méthylpoly(oxyéthylène)]oxy]propyl]-1-163-facteur de croissance et de développement de mégakaryocyte (humain)
pegacaristim	*N*-(3-hidroxipropil)-1-163-factor de desarrollo y crecimiento de megacariocitos (humano), monoéter con el éter monometílico de polietilenglicol



pegnartograstimum

pegnartograstim — *N*-L-methionyl-1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine colony-stimulating factor (human clone 1034), reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether

pégnartograstim — esters entre le produit de réaction du *N*-L-méthionyl-[1-L-alanine-3-L-thréonine-4-L-tyrosine-5-L-arginine-17-L-sérine] facteur de stimulation de colonie (clone humain 1034) avec l'anhydride succinique et le α-méthyl-ω-hydroxypoly(oxyéthylène)

pegnartograstim — ésteres con el éter monometilico de polietilenglicol del producto de reacción con anhidrido succinico del *N*-L-metionil-1-L-alanina-3-L-treonina-4-L-tirosina-5-L-arginina-17-L-serina-factor-estimulante de colonias (clon humano 1034)



ponazurilum

ponazuril — 1-methyl-3-[4-[*p*-[(trifluoromethyl)sulfonyl]phenoxy]-*m*-tolyl]-*s*-triazine-2,4,6(1*H*,3*H*,5*H*)-trione

ponazuril — 1-méthyl-3-[3-méthyl-4-[4-[(triflorométhyl)sulfonyl]phénoxy]phényl]-1,3,5-triazine-2,4,6(1*H*,3*H*,5*H*)-trione

ponazurilo — 1-metil-3-[4-[*p*-[(trifluorometil)sulfonil]fenoxi]-*m*-tolil]-*s*-triazina-2,4,6(1*H*,3*H*,5*H*)-triona

$C_{18}H_{14}F_3N_3O_6S$



rofecoxibum

rofecoxib — 4-[*p*-(methylsulfonyl)phenyl]-3-phenyl-2(5*H*)-furanone

rofécoxib — 4-[4-(méthylsulfonyl)phényl]-3-phénylfuran-2(5*H*)-one

rofecoxib — 4-[*p*-(metilsulfonil)fenil]-3-fenil-2(5*H*)-furanona

$C_{17}H_{14}O_4S$



sarizotanum

sarizotan — (-)-3-[[[(*R*)-2-chromanylmethyl]amino]methyl]-5-(*p*-fluorophenyl)pyridine

sarizotan — (-)-*N*-[[(2*R*)-3,4-dihydro-2*H*-chromén-2-yl]méthyl][5-(4-fluorophényl)pyridin-3-yl]méthanamine

sarizotán — (-)-3-[[[(*R*)-2-cromanilmetil]amino]metil]-5-(*p*-fluorofenil)piridina

$C_{22}H_{21}FN_2O$



satraplatinum

satraplatin — (*OC*-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum

satraplatine — (*OC*-6-43)-bis(acétato)amminedichloro(cyclohexanamine)platine

satraplatino — (*OC*-6-43)-bis(acetato)aminadicloro(ciclohexilamina)platino

$C_{10}H_{22}Cl_2N_2O_4Pt$



semparatidum

semparatide — L-alanyl-L-valyl-L-seryl-L-α-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-α-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-α-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-L-alaninamide

semparatide — L-alanyl-L-valyl-L-seryl-L-glutamyl-L-histidyl-L-glutaminy-L-leucyl-L-leucyl-L-histidyl-L-aspartyl-L-lysyl-glycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-histidyl-L-thréonyl-L-alaninamide

semparatida — L-alanil-L-valil-L-seril-L-α-glutamil-L-histidil-L-glutaminil-L-leucil-L-leucil-L-histidil-L-α-aspartil-L-lisilglicil-L-lisil-L-seril-L-isoleucil-L-glutaminil-L-α-aspartil-L-leucil-L-arginil-L-arginil-L-arginil-L-α-glutamil-L-leucil-L-leucil-L-α-glutamil-L-lisil-L-leucil-L-leucil-L-α-glutamil-L-lisil-L-leucil-L-histidil-L-treonil-L-alaninamida

$C_{175}H_{300}N_{56}O_{51}$

Ala—Val—Ser—Glu—His—Gln—Leu—Leu—His—Asp—
10
Lys—Gly—Lys—Ser—Ile—Gln—Asp—Leu—Arg—Arg—
20
Arg—Glu—Leu—Leu—Glu—Lys—Leu—Leu—Glu—Lys—
30
Leu—His—Thr—Ala—NH_2

simeticonum

simeticone — α-(trimethylsilyl)-ω-methylpoly[oxy(dimethylsilylene)], mixture with silicon dioxide

siméticone — mélange de α-(triméthylsilyl)-ω-méthylpoly[oxy(diméthylsilylène)] et de dioxyde de silicium

simeticona — α-(trimetilsilil)-ω-metilpoli[oxi(dimetilsilileno)], mezcla con dióxido de silicio

sitamaquinum

sitamaquine — 8-[[6-(diethylamino)hexyl]amino]-6-methoxy-4-methylquinoline

sitamaquine — *N,N*-diéthyl-*N'*-(6-méthoxy-4-méthylquinoléin-8-yl)hexane-1,6-diamine

sitamaquina — 8-[[6-(dietilamino)hexil]amino]-6-metoxi-4-metilquinolina

$C_{21}H_{33}N_3O$



solimastatum

solimastat — (2*S*,3*R*)-3-[[(1*S*)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanohydroxamic acid

solimastat — (2*R*,3*S*)-N^1-[(1*S*)-2,2-diméthyl-1-[(pyridin-2-yl)carbamoyl]propyl]-N^4-hydroxy-3-méthoxy-2-(2-méthylpropyl)butanediamide

solimastat — ácido (2*S*,3*R*)-3-[[(1*S*)-2,2-dimetil-1-(2-piridilcarbamoil)propil]carbamoil]-2-metoxi-5-metilhexanohidroxámico

$C_{20}H_{32}N_4O_5$



sonepiprazolum

sonepiprazole — (-)-*p*-[4-[2-[(*S*)-1-isochromanyl]ethyl]-1-piperazinyl]benzenesulfonamide

sonépiprazole — (-)-4-[4-[2-[(1*S*)-3,4-dihydro-1*H*-isochromén-1-yl]éthyl]pipérazin-1-yl]benzènesulfonamide

sonepiprazol — (-)-*p*-[4-[2-[(*S*)-1-isocromanil]etil]-1-piperazinil]bencenosulfonamida

$C_{21}H_{27}N_3O_3S$



tabimorelinum

tabimorelin — (*R*)-α-[(*E*)-5-amino-*N*,5-dimethyl-2-hexenamido]-*N*-methyl-*N*-[(*R*)-α-(methylcarbamoyl)phenethyl]-2-naphthalenepropionamide

tabimoréline — (*E*)-5-amino-*N*-[(1*R*)-2-[[(1*R*)-1-benzyl-2-(méthylamino)-2-oxoéthyl]=éthylamino]-1-(naphtalén-2-ylméthyl)-2-oxoéthyl]-*N*,5-diméthylhex-2-énamide

tabimorelina — (*R*)-α-[(*E*)-5-amino-*N*,5-dimetil-2-hexenamido]-*N*-metil-*N*-[(*R*)-α-(metilcarbamoil)fenetil]-2-naftalenopropionamid

$C_{32}H_{40}N_4O_3$



tafenoquinum

tafenoquine (±)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[(α,α,α-trifluoro-*m*-tolyl)oxy]quinoline

tafénoquine (4*RS*)-N^4-[2,6-diméthoxy-4-méthyl-5-[3-(trifluorométhyl)phénoxy]quinoléin-8-yl]pentane-1,4-diamine

tafenoquina (±)-8-[(4-amino-1-metilbutil)amino]-2,6-dimetoxi-4-metil-5-[(α,α,α-trifluoro-*m*-tolil)oxi]quinolina

$C_{24}H_{28}F_3N_3O_3$



and enantiomer
et énantiomère
y enantiómero

talampanelum

talampanel (*R*)-7-acetyl-5-(*p*-aminophenyl)-8,9-dihydro-8-methyl-7*H*-1,3-dioxolo=[4,5-*h*][2,3]benzodiazepine

talampanel (8*R*)-7-acétyl-5-(4-aminophényl)-8-méthyl-8,9-dihydro-7*H*-1,3-dioxolo=[4,5-*h*][2,3]benzodiazépine

talampanel (*R*)-7-acetil-5-(*p*-aminofenil)-8,9-dihidro-8-metil-7*H*-1,3-dioxolo=[4,5-*h*][2,3]benzodiazepina

$C_{19}H_{19}N_3O_3$



telithromycinum

telithromycin (3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-*xylo*-hexopyranosyl]oxy]-2*H*-oxacyclotetradecino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tetrone

télithromycine (3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-10-[[3-(diméthylamino)-3,4,6-tridésoxy-β-D-*xylo*-hexopyranosyl]oxy]-4-éthyl-11-méthoxy-3a,7,9,11,13,15-hexaméthyl-1-[4-[4-(pyridin-3-yl)-1*H*-imidazol-1-yl]butyl]= octahydro-2*H*-oxacyclotétradécino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tétrone

telitromicina (3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-etiloctahidro-11-metoxi-3a,7,9,11,13,15-hexametil-1-[4-[4-(3-piridil)imidazol-1-il]butil]-10-[[3,4,6-tridesoxy-3-(dimetilamino)-β-D-*xilo*-hexopiranosil]oxi]-2*H*-oxaciclotetradecino[4,3-*d*]oxazol-2,6,8,14(1*H*,7*H*,9*H*)-tetrona

$C_{43}H_{65}N_5O_{10}$



tenatoprazolum

tenatoprazole (±)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1*H*-imidazo[4,5-*b*]pyridine

ténatoprazole 5-méthoxy-2-[(*RS*)-[(4-méthoxy-3,5-diméthylpyridin-2-yl)méthyl]sulfinyl]-1*H*-imidazo[4,5-*b*]pyridine

tenatoprazol (±)-5-metoxi-2-[[(4-metoxi-3,5-dimetil-2-piridil)metil]sulfinil]-1*H*-imidazo[4,5-*b*]piridina

$C_{16}H_{18}N_4O_3S$



and enantiomer
et énantiomère
y enantiómero

teriflunomidum

teriflunomide (*Z*)-2-cyano-α,α,α-trifluoro-3-hydroxy-*p*-crotonotoluidide

tériflunomide (*Z*)-2-cyano-3-hydroxy-*N*-[4-(trifluorométhyl)phényl]but-2-énamide

teriflunomida (*Z*)-2-ciano-α,α,α-trifluoro-3-hidroxi-*p*-crotonotoluidida

$C_{12}H_9F_3N_2O_2$



timcodarum

timcodar (*S*)-*N*-benzyl-*p*-chloro-α-[*N*-methyl-2-(3,4,5-trimethoxyphenyl)glyoxylamido]-*N*-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]hydrocinnamamide

timcodar (2*S*)-*N*-benzyl-3-(4-chlorophényl)-2-[méthyl[2-oxo-2-(3,4,5-triméthoxyphényl)acétyl]amino]-*N*-[3-(pyridin-4-yl)-1-[2-(pyridin-4-yl)éthyl]propyl]propanamide

timcodar (*S*)-*N*-bencil-p-cloro-α-[*N*-metil-2-(3,4,5-trimetoxifenil)glioxilamido]=*N*-[3-(4-piridil)-1-[2-(4-piridil)etil]propil]hidrocinamamida

$C_{43}H_{45}ClN_4O_6$



tipranavirum

tipranavir — 3'-[(1*R*)-1-[(6*R*)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2*H*-pyran-3-yl]propyl]-5-(trifluoromethyl)-2-pyridinesulfonanilide

tipranavir — *N*-[3-[(1*R*)-1-[(6*R*)-4-hydroxy-2-oxo-6-(2-phényléthyl)-6-propyl-5,6-dihydro-2*H*-pyran-3-yl]propyl]phényl]-5-(trifluorométhyl)pyridine-2-sulfonamide

tipranavir — 3'-[(1*R*)-1-[(6*R*)-5,6-dihidro-4-hidroxi-2-oxo-6-fenetil-6-propil-2*H*-piran-3-il]propil]-5-(trifluorometil)-2-piridinasulfonanilida

$C_{31}H_{33}F_3N_2O_5S$



tonabersatum

tonabersat — *N*-[(3*S*,4*S*)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-3-chloro-4-fluorobenzamide

tonabersate — *N*-[(3*S*,4*S*)-6-acétyl-3-hydroxy-2,2-diméthyl-3,4-dihydro-2*H*-chromén-4-yl]-3-chloro-4-fluorobenzamide

tonabersato — *N*-[(3*S*,4*S*)-6-acetil-3-hidroxi-2,2-dimetil-4-cromanil]-3-cloro-4-fluorobenzamida

$C_{20}H_{19}ClFNO_4$



tositumomabum

tositumomab — immunoglobulin G2a anti-(human antigen CD 20) (mouse monoclonal clone B1R1 γ2a-chain), disulfide with mouse monoclonal clone B1R1 λ_x-chain, dimer

tositumomab — immunoglobuline G2a anti-(antigène CD 20 humain) (chaîne γ2a de l'anticorps monoclonal de souris B1R1), dimère du disulfure avec la chaîne λ_x de l'anticorps monoclonal de souris B1R1

tositumomab — Inmunoglobulina G2a anti-(antígeno CD 20 humano) (cadena γ2a del anticuerpo monoclonal de ratón B1R1),dímero del disulfuro con la cadena λ_x del anticuerpo monoclonal de ratón B1R1

travoprostum

travoprost — isopropyl (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*,3*R*)-3-hydroxy-4-[(α,α,α–trifluoro-*m*-tolyl)oxy]-1-butenyl]cyclopentyl]-5-heptenoate

travoprost — (5*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*)-(3*R*)-3-hydroxy-4-[3-(trifluorométhyl)phénoxy]but-1-ényl]cyclopentyl]hept-5-énoate de 1-méthyléthyle

travoprost — (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihidroxi-2-[(1*E*,3*R*)-3-hidroxi-4-[(α,α,α-trifluoro-*m*-tolil)oxi]-1-butenil]ciclopentil]-5-heptenoato de isopropilo

$C_{26}H_{35}F_3O_6$



valdecoxibum

valdecoxib — *p*-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide

valdécoxib — 4-(5-méthyl-3-phénylisoxazol-4-yl)benzènesulfonamide

valdecoxib — *p*-(5-metil-3-fenil-4-isoxazolil)bencenosulfonamida

$C_{16}H_{14}N_2O_3S$



vangatalcitum

vangatalcite — dialuminum tetramagnesium carbonate dodecahydroxide trihydrate

vangatalcite — carbonate et dodécahydroxyde de dialuminium et de tétramagnésium trihydraté

vangatalcita — dodecahidróxido carbonato de dialuminio y tetramagnesio trihidrato

$Al_2Mg_4(OH)_{12}CO_3, 3\ H_2O$

vepalimomabum

vepalimomab — immunoglobulin M (mouse monoclonal 1B2 μ-chain anti-human vascular adhesion protein VAP-1), disulfide with mouse monoclonal 1B2 light chain, dimer

vépalimomab — immunoglobuline M anti-(protéine d'adhésion vasculaire humaine VAP-1) (chaîne μ de l'anticorps monoclonal de souris 1B2), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 1B2

vepalimomab — inmunoglobulina M (cadena μ del anticuerpo monoclonal de ratón 1B2 dirigido contra la proteína humana de adhesión vascular VAP-1), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 1B2

volpristinum

volpristin — (3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,26a*R*)-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo=[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4*H*,17*H*)-tetrone

volpristine — (5*E*,10*E*,12*E*)-(3*R*,4*R*,14*S*,26a*R*)-14-hydroxy-4,12-diméthyl-3-(1-méthyléthyl)-3,4,8,9,14,15,24,25,26,26a-décahydro-7*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo=[2,1-c][1,8,4,19]dioxadiazacyclotétracosène-1,7,16,22(17*H*)-tétrone

volpristina — (3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,26a*R*)-8,9,14,15,24,25,26,26a-octahidro-14-hidroxi-3-isopropil-4,12-dimetil-3*H*-21,18-nitrilo-1*H*,22*H*-pirrolo=[2,1-c][1,8,4,19]dioxadiazaciclotetracosina-1,7,16,22(4*H*,17*H*)-tetrona

$C_{28}H_{37}N_3O_7$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 29
(WHO Drug Information, Vol. 3, No. 3, 1989)

p. 4 **dexmedetomidinum**
dexmedetomidine

replace the chemical name and the graphic formula by the following:
(+)-(*S*)-4-[1-(2,3-dimethylphenyl)ethyl]-1*H*-imidazole



Dénominations communes internationales recommendées (DCI Rec.): Liste 29
(Informations Pharmaceutiques OMS, *Vol. 3, No. 3, 1989)*

p. 4 **dexmedetomidinum**
dexmédétomidine

remplacer le nom chimique et la formule developpée par:
(+)-(*S*)-4-[1-(2,3-diméthylphényl)éthyl]-1*H*-imidazole



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 29
(Información Farmacéutica OMS, *Vol. 3, No. 3, 1989)*

p. 4 **dexmedetomidinum**
dexmedetomidina

sustitúyanse el nombre quimico y la fórmula desarrollada por:
(+)-(*S*)-4-[1-(2,3-dimetilfenil)etil]-1*H*-imidazol



Recommended International Nonproprietary Names (Rec. INN): List 36
Dénominations communes internationales recommedées (DCI Rec.): Liste 36
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 36
(WHO Drug Information, Vol. 10, No. 3, 1996)

p. 153 **odulimomabum**

odulimomab	*replace the description by the following:* immunoglobulin G1, anti-(human CD11 (antigen) α-chain) (mouse monoclonal 25.3 γ1-chain), disulfide with mouse monoclonal 25.3 light chain, dimer
odulimomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(chaîne α de l'antigène CD11 humain) (chaîne γ1 de l'anticorps monoclonal de souris 25.3), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 25.3
odulimomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-(cadena α del antígeno CD11 humano) (cadena γ1 del anticuerpo monoclonal de ratón 25.3), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 25.3

Recommended International Nonproprietary Names (Rec. INN): List 37
Dénominations communes internationales recommedées (DCI Rec.): Liste 37
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 37
(WHO Drug Information, Vol. 11, No. 1, 1997)

p. 35 **bectumomabum**

bectumomab	*replace the description by the following:* immunoglobulin G2a, anti-(human CD22 (antigen)) Fab' fragment (mouse monoclonal IMMU-LL23 γ2a-chain), disulfide with mouse monoclonal IMMU-LL2 light chain
bectumomab	*remplacer la description par la suivante:* immunoglobuline G2a, anti-(antigène CD22 humain) fragment Fab' (chaîne γ2a de l'anticorps monoclonal de souris IMMU-LL2), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-LL2
bectumomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G2a, anti-(antígeno CD22 humano) fragmento Fab' (cadena γ2a del anticuerpo monoclonal de ratón IMMU-LL2), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-LL2

p. 48 **sulesomabum**

sulesomab	*replace the description by the following:* immunoglobulin G1, anti-(human NCA-90 granulocyte cell antigen) Fab' fragment (mouse monoclonal IMMU-MN3 γ1-chain), disulfide with mouse monoclonal IMMU-MN3 light chain
sulésomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(antigène cellulaire NCA-90 de granulocyte humain) fragment Fab' (chaîne γ1 de l'anticorps monoclonal de souris IMMU-MN3), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-MN3
sulesomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-(antígeno NCA-90 de células de granulocito humano) fragmento Fab' (cadena γ1 del anticuerpo monoclonal de ratón IMMU-MN3), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-MN3

p. 49 **technetium (^{99m}Tc) pintumomabum**

technetium (^{99m}Tc) pintumomab	*replace the description by the following:* immunoglobulin G1, anti-(human adenocarcinoma antigen) (mouse monoclonal 170 γ1-chain), disulfide with mouse monoclonal 170 κ-chain, dimer, technetium [^{99m}Tc] salt
technétium (^{99m}Tc) pintumomab	*remplacer la description par la suivante:* sel de [^{99m}Tc]technétium de l'immunoglobuline G1, anti-(antigène associé aux adénocarcinomes humains) (chaîne γ1 de l'anticorps monoclonal de souris 170), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris 170
tecnecio (^{99m}Tc) pintumomab	*sustitúyase la descripción por la siguiente:* sal de [^{99m}Tc]tecnecio del inmunoglobulina G1, anti-(antígeno asociado a los adenocarcinomas humanos) fragmento Fab' (cadena γ1 del anticuerpo monoclonal de ratón 170), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón 170

Recommended International Nonproprietary Names (Rec. INN): List 38
Dénominations communes internationales recommedées (DCI Rec.): Liste 38
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 38
(WHO Drug Information, Vol. 11, No. 3, 1997)

p. 161 **basiliximabum**

basiliximab	*replace the description by the following:* immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal CHI621 γ1-chain), disulfide with human-mouse monoclonal CHI621 light chain, dimer

basiliximab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(récepteur de l'interleukine 2 humain) (chaîne γ1 de l'anticorps monoclonal chimérique homme-souris CHI621), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris CHI621
basiliximab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-(receptor de interleukina 2 humano) (cadena γ1 del anticuerpo monoclonal hombre-ratón CHI621), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón CHI621

p. 174 **nerelimomabum**

nerelimomab	*replace the description by the following:* immunoglobulin G1, anti-(human tumor necrosis factor α) (mouse monoclonal BAYX1351 γ1-chain), disulfide with mouse monoclonal BAYX1351 light chain, dimer
nérélimomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(facteur de nécrose tumorale α humain) (chaîne γ1 de l'anticorps monoclonal de souris BAYX1351), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BAYX1351
nerelimomab	*sustitúyase el nombre químico por:* inmunoglobulina G1, anti-(factor de necrosis tumoral α humano) (cadena γ1 del anticuerpo monoclonal de ratón BAYX1351), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón BAYX1351

p. 178 **technetium (^{99m}Tc) nofetumomabum merpentanum**

technetium (^{99m}Tc) nofetumomab merpentan	*replace the description by the following:* immunoglobulin G2b, anti-(human tumor) Fab fragment (mouse monoclonal NR-LU-10 γ2b-chain), disulfide with mouse monoclonal NR-LU-10 κ-chain, oxo[[*N,N'*-[1-(3-oxopropyl)-1,2-ethanediyl]bis[2-mercaptoacetamidato]]= (4-)-*N,N',S,S'*]technetate(1-)-[^{99m}Tc] conjugate
technétium (^{99m}Tc) nofétumomab merpentan	*remplacer la description par la suivante:* immunoglobuline G2b, anti-(tumeur humaine) fragment Fab (chaîne γ2b de l'anticorps monoclonal de souris NR-LU-10), disulfure avec la chaîne κ de l'anticorps monoclonal de souris NR-LU-10, conjuguée avec l'oxo= [[*N,N'*-[1-(3-oxopropyl)éthylène]bis[2-sulfanylacétamidato]]= (4-)-*N,N',S,S'*][^{99m}Tc]technétate(1-)
tecnecio (^{99m}Tc) nofetumomab merpentán	*sustitúyase el nombre químico por:* inmunoglobulina G2b, anti-(tumor humano) fragmento Fab (cadena γ2b del anticuerpo monoclonal de ratón NR-LU-10), disulfuro con la cadena κ del anticuerpo monoclonal de ratón NR-LU-10, conjugado con el oxo[[*N,N'*-[1-(3-oxopropil)etano-1,2-diil]bis[2-sulfanilacetamidato]]= (4-)-*N,N',S,S'*][^{99m}Tc]tecnetato(1-)

Proposed International Nonproprietary Names (Rec. INN): List 39
Dénominations communes internationales proposées (DCI Rec.): Liste 39
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 39
(WHO Drug Information, Vol. 12, No. 1, 1998)

p. 43 **cedelizumabum**

cedelizumab	*replace the description by the following:* immunoglobulin G4, anti-(human CD4 (antigen)) (human-mouse monoclonal OKTcdr4a complementary determining region-grafted γ4-chain), disulfide with human-mouse monoclonal OKTcdr4a complementary determining region-grafted κ-chain, dimer
cédélizumab	*remplacer la description par la suivante:* immunoglobuline G4, anti-(antigène CD4 humain) (chaîne γ4 de l'anticorps monoclonal de souris OKTcdr4a humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris OKTcdr4a humanisé
cedelizumab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G4, anti-(antígeno CD4 humano) (cadena γ4 del anticuerpo monoclonal humanizado de ratón OKTcdr4a), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón OKTcdr4a

p. 148 **igovomabum**

igovomab	*replace the description by the following:* immunoglobulin G1, anti-(human CA 125 (carbohydrate antigen)) $F(ab')_2$ fragment (mouse monoclonal $OC125F(AB')_2$ γ1-chain), disulfide with mouse monoclonal $OC125F(AB')_2$ light chain, dimer
igovomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(antigène osidique CA 125 humain) fragment $F(ab')_2$ (chaîne γ1 de l'anticorps monoclonal de souris $OC125F(AB')_2$), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris $OC125F(AB')_2$
igovomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-[(antígeno hidrato de carbono) CA 125 humano] (fragmento $F(ab')_2$ (cadena γ1 del anticuerpo monoclonal de ratón $OC125F(AB')_2$), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón $OC125F(AB')_2$

Proposed International Nonproprietary Names (Rec. INN): List 40
Dénominations communes internationales proposées (DCI Rec.): Liste 40
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 40
(WHO Drug Information, Vol. 12, No. 2, 1998)

p. 181 **fidarestatum**

fidarestat	*replace the graphic formula by the following:*
fidarestat	*remplacer la formule developpée par:*
fidarestat	*sustitúyase la fórmula desarrollada por:*



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internatio-nales applicables aux substances pharmaceutiques* ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sus-tancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacio-nales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.